Presidio Pharmaceuticals Inc. Raises $27 Million in Additional Financing

SAN FRANCISCO--(Business Wire)--
Presidio Pharmaceuticals Inc. announced today the closing of a financing round
of $27 million bringing the total raised to $54.5 million.

New Leaf Venture Partners joined the current investor syndicate comprised of
Panorama Capital, Baker Brothers Investments, Ventures West Capital, Bay City
Capital, Nexus Medical Partners and Sagamore BioVentures, in participating in
the financing. The funds raised will be used to advance Presidio`s HCV NS5A
clinical candidate through clinical studies, and to support the development of
other programs in the pipeline.

"I`m very pleased with the support we`ve received from our investors during the
challenging financing environment for the biotechnology sector," commented Omar
Haffar, Presidio`s President and CEO. "I`m also very pleased that New Leaf
Venture Partners decided to join the investor syndicate which underscores the
significant progress the Company has made in building value for our investors
over the three years since our founding."

Dr. Srinivas Akkaraju, Managing Director with New Leaf Venture Partners, will
represent NLV on Presidio`s Board of Directors. Dr. Akkaraju said, "We look
forward to working with Presidio`s exceptional management team as they advance
their highly potent NS5A inhibitors through clinical development. We believe
this program has the potential to further the evolution of HCV treatment by both
improving HCV cure rates and decreasing treatment burden."

Representing the existing investors, Kenneth Galbraith, General Partner with
Ventures West Capital and Chairman of the Board said, "With continued
participation from all existing investors and the addition of NLV as a
significant investor, we`re confident that Presidio is well-capitalized to
pursue clinical development of a potential best-in-class approach to treating
patients with chronic HCV infections."

About NLV Partners

NLV Partners is a life science-dedicated venture capital firm with offices in
Menlo Park and New York. Founded by an experienced team of venture capitalists
with deep healthcare industry experience, NLV Partners invests primarily in
companies focused on clinical-stage biopharmaceutical products, early-stage
medical devices and molecular diagnostics. NLV Partners manages over $1.3
billion of assets, including NLV-I, NLV-II and the healthcare technology
portfolio of Sprout Group. For further information, visit the NLV Partners
website at www.nlvpartners.com.

About Presidio

Presidio Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
the discovery, in-licensing, development and commercialization of novel
therapeutics for viral infections, including HIV-1 and HCV. For more
information, please visit our website at www.presidiopharma.com.

Presidio Pharmaceuticals, Inc.
Omar K. Haffar, Ph.D., 415-655-7561
President and Chief Executive Officer
omar@presidiopharma.com

Copyright Business Wire 2009